---
document_datetime: 2024-12-16 15:47:09
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hefiya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: hefiya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.4721642
conversion_datetime: 2025-12-28 19:52:30.071645
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hefiya

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2764/G            | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and | 12/12/2024                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                     |            |     |                                                                                                                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2630   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                             | 11/04/2024 | n/a |                                                                                                                                                               |
| WS/2675   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.3.z - Change in test procedure for the immediate packaging of the finished product - Other variation                                                                                        | 04/04/2024 | n/a |                                                                                                                                                               |
| WS/2591/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13: Submission of the final report from study RABBIT. This is a German registry for the long-term observation of therapy with biologics in adult patients with rheumatoid arthritis. | 11/01/2024 | n/a | The safety profile of adalimumab is well characterised, and no new safety issues were identified in the 3 category 3 studies. No SmPC updates were necessary. |

<div style=\"page-break-after: always\"></div>

|             | C.I.13: Submission of the final report from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This is a registry to investigate the long-term safety outcomes of psoriasis patients treated with biologic therapy. C.I.13: Submission of the final report from the Inflammatory Bowel Disease Registry (UK-IBD). This registry was used to identify adverse reactions to Hyrimoz in a cohort of inflammatory bowel disease patients managed in a real-world setting. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |            |              |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------|
| N/0051      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/12/2023 | 12/08/2024 | PL           |
| IB/0049     | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/10/2023 | n/a        |              |
| IAIN/0048/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2023 | 12/08/2024 | Annex II and |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.b.2.c.1 - Change to arrangements and quality Replacement or addition responsible for importation Not including batch control/testing A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the   | PL   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

| PSUSA/10783 /202212   | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                           | 31/08/2023   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IB/0046               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                | 07/08/2023   | 12/08/2024 | SmPC, Labelling and PL |                                     |
| IB/0045/G             | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                           | 26/07/2023   | n/a        |                        |                                     |
| IB/0044               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                         | 13/06/2023   | n/a        |                        |                                     |
| IG/1628/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form | 02/06/2023   | n/a        |                        |                                     |
| IB/0042               | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other                                                                                                                                                                                                                                                  | 28/04/2023   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | to a test procedure (including replacement addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  | changes or   |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------|
| X/0036/G | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency B.II.a.5 - Change in concentration of a single-dose, total use parenteral product, where the amount of AS per unit dose (i.e. the strength) remains the same B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 26/01/2023 | 31/03/2023 | SmPC, Annex II, Labelling and PL |              |

<div style=\"page-break-after: always\"></div>

| B.I.a.4.z - Change to applied during the manufacture variation B.I.a.4.z - Change to applied during the manufacture variation B.I.b.2.d - Change in starting material/reagent/intermediate change to or replacement biological/immunological/immunochemical method or a method using biological AS B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |             |                                                                                                                                                                                                                                                                      |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1601 | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                              | 22/03/2023 | n/a        |             |                                                                                                                                                                                                                                                                      |
| R/0038  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                 | 15/12/2022 | 06/02/2023 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Hefiya in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0039 | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                            | 18/10/2022 | n/a        |             |                                                                                                                                                                                                                                                                      |
| N/0037  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                        | 15/07/2022 | 06/02/2023 | PL          |                                                                                                                                                                                                                                                                      |
| IG/1480 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                        | 02/02/2022 | n/a        |             |                                                                                                                                                                                                                                                                      |
| IB/0034 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                              | 20/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 01/10/2021 | 19/10/2021 | SmPC and PL            |                                                                                                                                         |
| WS/1908/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 22/07/2021 | n/a        |                        |                                                                                                                                         |
| IB/0031   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/06/2021 | 19/10/2021 | SmPC, Labelling and PL | Type IB (B.II.f.1.d) - Removal of the 'do not shake' warning from the PI. Article 61(3) notifications - Update of local representatives |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             | list included in the patient information leaflet.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------|
| IG/1400/G           | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 31/05/2021 | n/a        |             |                                                     |
| WS/2025             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                          | 09/04/2021 | n/a        |             |                                                     |
| IG/1380             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                      | 26/03/2021 | 19/10/2021 | SmPC and PL |                                                     |
| IB/0027             | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                                                                                                                                                                                                                                                         | 11/11/2020 | n/a        |             |                                                     |
| IG/1290             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                      | 05/10/2020 | 19/02/2021 | SmPC and PL |                                                     |
| PSUSA/10783 /201912 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                                                                                            | 03/09/2020 | n/a        |             | PRAC Recommendation - maintenance                   |

<div style=\"page-break-after: always\"></div>

| IG/1288   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                | 27/08/2020   | n/a        |                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| IB/0023   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                   | 20/07/2020   | 19/02/2021 | SmPC and PL                      |
| IB/0021/G | This was an application for a group of variations. B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 17/06/2020   | n/a        |                                  |
| IA/0022   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                        | 08/06/2020   | n/a        |                                  |
| X/0013    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                            | 30/01/2020   | 27/03/2020 | SmPC, Annex II, Labelling and PL |
| IG/1190/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                    | 26/03/2020   | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                     |            |            |      |                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------|
| WS/1765   | application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by  | 05/03/2020 | 19/02/2021 | SmPC | This was an the MAH |
| IB/0017   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                 | 10/12/2019 | n/a        |      |                     |
| IA/0016/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the including quality control sites | 26/09/2019 | n/a        |      | finished product,   |

<div style=\"page-break-after: always\"></div>

|                     | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |           |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| WS/1643/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits | 19/09/2019 | n/a        |           |                                   |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/08/2019 | 27/03/2020 | Labelling |                                   |
| IA/0014             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/07/2019 | n/a        |           |                                   |
| PSUSA/10589 /201812 | Periodic Safety Update EU Single assessment - adalimumab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/07/2019 | n/a        |           | PRAC Recommendation - maintenance |
| IA/0011             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                     | 11/06/2019 | n/a        |           |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0010/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/05/2019   | 08/07/2019   | SmPC and PL                      |         |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------|
|             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by |              |              |                                  | the MAH |
| WS/1565     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                     | 28/03/2019   | 08/07/2019   | SmPC, Annex II, Labelling and PL |         |

<div style=\"page-break-after: always\"></div>

| IB/0007/G   | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other   | 21/03/2019   | n/a        |      |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|
| IB/0006     | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/02/2019   | 08/07/2019 | SmPC |
| WS/1479/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/01/2019   | n/a        |      |

<div style=\"page-break-after: always\"></div>

|             | Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products   |            |     | A.5.b -   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IAIN/0005/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                             | 20/12/2018 | n/a |           |
| IB/0004     | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2018 | n/a |           |
| IAIN/0003   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/11/2018 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IB/0002/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a   | 15/10/2018   | 08/07/2019   | SmPC, Annex II, Labelling and PL   |
|-------------|--------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|